Merck Provides Update on Phase 3 KEYNOTE-062 Trial Evaluating KEYTRUDA

Merck finds Keytruda no better than chemo as a first-line treatment for gastric cancer, according to a Phase 3 study. Results of which will be presented at the 55th annual ASCO meeting on June 2nd.